

# Peng Zou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2593849/publications.pdf>

Version: 2024-02-01

43  
papers

2,209  
citations

257450

24  
h-index

265206

42  
g-index

46  
all docs

46  
docs citations

46  
times ranked

3473  
citing authors

#	ARTICLE	IF	CITATIONS
1	Does Food Affect the Pharmacokinetics of Non-orally Delivered Drugs? A Review of Currently Available Evidence. <i>AAPS Journal</i> , 2022, 24, 59.	4.4	3
2	Developing an In Vitro to In Vivo Extrapolation (IVIVE) Model to Predict Human Milk-to-Plasma Drug Concentration Ratios. <i>Molecular Pharmaceutics</i> , 2022, 19, 2506-2517.	4.6	9
3	Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins. <i>Journal of Controlled Release</i> , 2021, 336, 310-321.	9.9	22
4	Biliary Excretion–Mediated Food Effects and Prediction. <i>AAPS Journal</i> , 2020, 22, 124.	4.4	7
5	Scientific and Regulatory Considerations for Generic Complex Drug Products Containing Nanomaterials. <i>AAPS Journal</i> , 2017, 19, 619-631.	4.4	39
6	How Has CDER Prepared for the Nano Revolution? A Review of Risk Assessment, Regulatory Research, and Guidance Activities. <i>AAPS Journal</i> , 2017, 19, 1071-1083.	4.4	22
7	Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products. <i>AAPS Journal</i> , 2017, 19, 1359-1376.	4.4	22
8	Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles. <i>AAPS Journal</i> , 2017, 19, 26-42.	4.4	114
9	The Effects of Pharmaceutical Excipients on Gastrointestinal Tract Metabolic Enzymes and Transporters—an Update. <i>AAPS Journal</i> , 2016, 18, 830-843.	4.4	52
10	A Global Perspective on First-in-Man Dose Selection: Oncology and Beyond. , 2016, , 39-58.		1
11	Product quality for nanomaterials: current U.S. experience and perspective. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2015, 7, 640-654.	6.1	51
12	Pharmacodynamic Endpoint Bioequivalence Studies. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014, , 217-241.	0.6	6
13	PLGA/Liposome Hybrid Nanoparticles for Short-Chain Ceramide Delivery. <i>Pharmaceutical Research</i> , 2014, 31, 684-693.	3.5	24
14	Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM406/AT406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 348-359.	1.9	16
15	Noninvasive Fluorescence Resonance Energy Transfer Imaging of <i>in Vivo</i> Premature Drug Release from Polymeric Nanoparticles. <i>Molecular Pharmaceutics</i> , 2013, 10, 4185-4194.	4.6	71
16	Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. <i>Journal of Controlled Release</i> , 2013, 172, 558-567.	9.9	10
17	A Potent Small-Molecule Inhibitor of the MDM2–p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5553-5561.	6.4	229
18	Polymeric Curcumin Nanoparticle Pharmacokinetics and Metabolism in Bile Duct Cannulated Rats. <i>Molecular Pharmaceutics</i> , 2013, 10, 1977-1987.	4.6	58

#	ARTICLE	IF	CITATIONS
19	Kinetics of sulforaphane in mice after consumption of sulforaphane-enriched broccoli sprout preparation. <i>Molecular Nutrition and Food Research</i> , 2013, 57, 2128-2136.	3.3	33
20	Comparison of In Vitro-In Vivo Extrapolation of Biliary Clearance Using an Empirical Scaling Factor Versus Transport-Based Scaling Factors in Sandwich-Cultured Rat Hepatocytes. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 2837-2850.	3.3	16
21	Applications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation. <i>AAPS Journal</i> , 2012, 14, 262-281.	4.4	91
22	Prediction of volume of distribution at steady state in humans: comparison of different approaches. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 855-872.	3.3	31
23	Intracellular dissociation of a polymer coating from nanoparticles. <i>Nano Research</i> , 2012, 5, 815-825.	10.4	22
24	Examination of the Pharmacokinetics of Active Ingredients of Ginger in Humans. <i>AAPS Journal</i> , 2011, 13, 417-26.	4.4	88
25	In Vitro Metabolism of 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin in Human Liver Microsomes. <i>Drug Metabolism and Disposition</i> , 2011, 39, 627-635.	3.3	10
26	Withaferin A targets heat shock protein 90 in pancreatic cancer cells. <i>Biochemical Pharmacology</i> , 2010, 79, 542-551.	4.4	254
27	<sup>124</sup> I-HuCC49 $\Delta$ CH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results. <i>World Journal of Surgical Oncology</i> , 2010, 8, 65.	1.9	16
28	Cells on Pores: A Simulation-Driven Analysis of Transcellular Small Molecule Transport. <i>Molecular Pharmaceutics</i> , 2010, 7, 456-467.	4.6	12
29	Superparamagnetic Iron Oxide Nanotheranostics for Targeted Cancer Cell Imaging and pH-Dependent Intracellular Drug Release. <i>Molecular Pharmaceutics</i> , 2010, 7, 1974-1984.	4.6	124
30	Characterization of Celastrol to Inhibit Hsp90 and Cdc37 Interaction. <i>Journal of Biological Chemistry</i> , 2009, 284, 35381-35389.	3.4	155
31	Near-Infrared Fluorescence Labeled Anti-TAG-72 Monoclonal Antibodies for Tumor Imaging in Colorectal Cancer Xenograft Mice. <i>Molecular Pharmaceutics</i> , 2009, 6, 428-440.	4.6	71
32	Identification of benzamidenafil, a new class of phosphodiesterase-5 inhibitor, as an adulterant in a dietary supplement. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 47, 255-259.	2.8	33
33	Isolation and identification of thiohomosildenafil and thiosildenafil in health supplements. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 47, 279-284.	2.8	71
34	Structural elucidation of a PDE-5 inhibitor detected as an adulterant in a health supplement. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 48, 1070-1075.	2.8	23
35	Detection of dehydroepiandrosterone and androsterone in a traditional Chinese herbal product. <i>Food Additives and Contaminants</i> , 2007, 24, 1326-1333.	2.0	3
36	Letter: Liquid Chromatography Ion-Trap Time-of-Flight Mass Spectrometric Study on the Fragmentation of an Acetildenafil Analogue. <i>European Journal of Mass Spectrometry</i> , 2007, 13, 233-238.	1.0	5

#	ARTICLE	IF	CITATIONS
37	Detection of sibutramine, its two metabolites and one analogue in a herbal product for weight loss by liquid chromatography triple quadrupole mass spectrometry and time-of-flight mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2007, 21, 614-618.	1.5	36
38	Determination of indican, isatin, indirubin and indigotin in <i>Indigofera tinctoria</i> by liquid chromatography/electrospray ionization tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2007, 21, 1239-1246.	1.5	60
39	Electrospray tandem mass spectrometric investigations of tadalafil and its analogue. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 3488-3490.	1.5	23
40	Simultaneous determination of synthetic phosphodiesterase-5 inhibitors found in a dietary supplement and pre-mixed bulk powders for dietary supplements using high-performance liquid chromatography with diode array detection and liquid chromatography/electrospray ionization tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2006, 1104, 113-122.	3.7	130
41	Detection of Sildenafil Analogues in Herbal Products for Erectile Dysfunction. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2006, 69, 1951-1958.	2.3	32
42	Structural elucidation of a tadalafil analogue found as an adulterant of a herbal product. <i>Food Additives and Contaminants</i> , 2006, 23, 446-451.	2.0	65
43	Structural identification of a new acetildenafil analogue from pre-mixed bulk powder intended as a dietary supplement. <i>Food Additives and Contaminants</i> , 2006, 23, 870-875.	2.0	48